Sentences with phrase «myeloma who»

They looked at data from 1,111 patients with newly diagnosed or relapsed / refractory myeloma who underwent transplant at the Mayo Clinic from 2007 to 2015.

Instead, newer trials have suggested that the use of minimal residual disease (MRD) status may be a valid surrogate outcomes for survival in patients with myeloma who achieved CR.

Pomalidomide plus low - dose dexamethasone administered in combination has shown efficacy in patients with relapsed or refractory myeloma who have normal kidney function or moderate renal impairment.

Multiple myeloma patients got some good news on November 16 — the immunotherapy daratumumab (Darzalex ®) was given approval by the FDA for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy.

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.

The U.S. Food and Drug Administration approved the drug on Nov. 20 for patients with myeloma who have received at least one previous therapy.

Empliciti will be used in combination with two other drugs to treat patients with multiple myeloma who have received one to three prior courses of medication.

Not exact matches

«The oncologist — who seemed to have been out of school the day they mentioned bedside manners — turned to me and said, «Well, you have a malignancy: It's called multiple myeloma.»

The FDA approved Kyprolis for patients who have already been treated with at least two other multiple myeloma drugs, and Onyx is conducting other trials to win broader marketing approval.

Roger Neilson desperately wants to coach again, but if no team is willing to put a 66 - year - old who is recovering from multiple myeloma behind the bench, then the league should add him to its hockey department.

Geraldine Ferraro, the first woman to run for vice president on a major party ticket and a congresswoman who championed Queens in the House for six years, died Saturday in Boston after a 12 - year battle with multiple myeloma, a blood cancer.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.

Figure on the right: Bortezomib treatment is significantly less effective in multiple myeloma patients who have suppressed expression of a 19s proteasome cap subunit.

Furthermore, the levels of Runx2 expression among a larger group of 351 newly diagnosed multiple myeloma patients were significantly higher in patients who had a high risk of early disease - related death, as compared with lower - risk patients.

«In summary, these encouraging data build upon the real success of our translational efforts in myeloma over the last decade, and provide exciting new options with the real promise of improving patient outcome,» said Richardson, who is also the R.J. Corman professor at Harvard Medical School.

«Today, we have half a dozen drugs for multiple myeloma that can put patients into remission,» said Tomasson, who treats patients with multiple myeloma at Siteman Cancer Center at Barnes - Jewish Hospital and Washington University School of Medicine.

«Patients who drew a round body shape had a higher incidence of multiple myeloma.»

For this analysis, 605 patients with newly diagnosed multiple myeloma and treated with continuous lenalidomide (brand name Revlimid) following autologous stem cell transplant were compared to 604 patients who were treated with placebo or no maintenance.

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

The 2 - year trial will treat 18 people with myeloma, sarcoma, or melanoma who have stopped responding to existing treatments at three sites that are members of the Parker Institute — UPenn; the University of California, San Francisco; and the University of Texas MD Anderson Cancer Center in Houston.

A study that used stored blood samples from U.S. Air Force personnel who conducted aerial herbicide spray missions of Agent Orange during the Vietnam war found a more than 2-fold increased risk of the precursor to multiple myeloma known as monoclonal gammopathy of undetermined significance (MGUS), according to an article published online by JAMA Oncology.

Dr Daniel Tennant, who led the research at the University of Birmingham, said, «Our findings show that very few changes are required for a MGUS patient to progress to myeloma as we now know virtually all patients with myeloma evolve from MGUS.

As an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia, lymphoma, and myeloma, the American Society of Hematology (ASH) is supportive of efforts to provide insurance parity for all approved evidence - based cancer treatments.

No Association Between Response Rates and Survival in Newly Diagnosed Multiple Myeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple myeloma in populations of patients who received stem cell transplant and those who dMyeloma: Results of a recent meta - regression analysis of 63 randomized clinical trials out of Greece concluded that there was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and overall (OS) or progression - free survival (PFS) in patients with newly diagnosed multiple myeloma in populations of patients who received stem cell transplant and those who dmyeloma in populations of patients who received stem cell transplant and those who did not.

The news was reported by his friend and collaborator William Friedkin, who stated that the cause of death was multiple myeloma.

Myeloma has different forms, but 90 percent of people who have been diagnosed with myeloma have multiple mMyeloma has different forms, but 90 percent of people who have been diagnosed with myeloma have multiple mmyeloma have multiple myelomamyeloma.